⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 11, 2024International Journal of STD & AIDS

Emtricitabine/tenofovir alafenamide and doravirine in a virologically suppressed adult with HIV and on chronic ambulatory peritoneal dialysis: A case report

Elizabeth M. Bickenbach Jonathan Pan Mackie King

View Full Paper

Ask AI

Bookmark

Share

Abstract

Data supporting the safe and effective use of first-line antiretroviral therapy in people living with HIV on hemodialysis or peritoneal dialysis remains limited. Previously in this journal, the first case report of BIC/FTC/TAF use in chronic ambulatory peritoneal dialysis was presented. We present the first known case of DOR + FTC/TAF in chronic ambulatory peritoneal dialysis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bickenbach et al. (2024) studied this question.

synapsesocial.com/papers/68e65543b6db6435875e3d83 https://doi.org/10.1177/09564624241259516

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis2024 · 2 citations
2Bictegravir/emtricitabine/tenofovir alafenamide in adults with <scp>HIV</scp>‐1 and end‐stage kidney disease on chronic haemodialysis2024
3Efficacy and Renal Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Among People Living With HIV With Early or Mild Renal Injury: A Real World Retrospective Study in ChinaRetrospective Study · 2026
4Comparative safety and efficacy of BIC/FTC/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort studyCohort Study · 2026
5Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF: Integrated Analysis from Nine Phase 3/3b Clinical TrialsLate-Phase Clinical Trial · 2026 · 1 citations